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Abstract
Castleman’s disease (CD) is a lymphoproliferative disorder, manifesting clinically as uni‐
centric or multicentric disease and pathologically as hyaline vascular, plasma cell or
mixed variants.
Multicentric Castleman’s disease (MCD) is the most common form of CD encountered at
Chris Hani Baragwanath Academic Hospital (CHBAH). From being a rare disease, MCD
has increased in the last five years, primarily as a result of the association of human im‐
munodeficiency virus (HIV), being highly prevalent in our patient population. The domi‐
nant clinical manifestations of the disease include constitutional symptoms, fever,
anaemia, lymphadenopathy and hepatosplenomegaly.
We present a series of 35 adult patients with MCD, who were seen over a 25-year period
at CHBAH, and highlight the similarities and differences compared with other published
series.
Based on our local experience, we observed that the prognosis of HIV-associated MCD
has improved with optimization and control of HIV replication (use of combination anti‐
retroviral therapy), prophylaxis and treatment of opportunistic infections, as well as eto‐
poside and rituximab based chemotherapy.
In the setting of HIV, MCD should no longer be regarded as a rare disease with a fatal
outcome.
Keywords: Multicentric Castleman’s disease, Human immunodeficiency virus infection,
Human herpes virus-8, South Africa, immunosuppression
1. Introduction
Castleman’s disease (CD), also known as angiofollicular or giant lymph node hyperplasia, is
a rare B-cell lymphoproliferative disorder, first described by Benjamin Castleman in a series
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of patients in 1956 [1]. It is a heterogeneous disorder, manifesting clinically as a unicentric
(solitary; localised) or multicentric disease and pathologically as hyaline vascular, plasma cell
or mixed variants [2–6].
The multicentric variety is aetiologically linked to human herpes virus-8 (HHV-8) [7]. It is
strongly associated with immunosuppression and is now being encountered with increasing
frequency in patients with HIV (human immunodeficiency virus) infection [8].
This review will focus on CD, with particular reference to Multicentric Castleman’s disease
(MCD), and it will include a description of the disease as seen at Chris Hani Baragwanath
Academic Hospital (CHBAH), Johannesburg, South Africa over a 25-year period (1990 to 2014).
The renewed interest in MCD stems from its association with HIV, particularly in areas such
as sub-Saharan Africa where HIV has reached pandemic proportions, with South Africa being
home to approximately 6.4 million people living with HIV/AIDS (acquired immunodeficiency
syndrome) [9].
2. Epidemiology
Castleman’s disease (CD), from being rare, is now more commonly encountered. In the last
three decades since the discovery of HIV, the incidence of MCD has progressively increased
over time. The median age at presentation of MCD is 40 (21–67) years, with a male predomi‐
nance of 90%, based on a systematic review of published cases in the literature up to 2007 [10].
A younger age at presentation is noted in HIV-seropositive individuals with MCD compared
to HIV-seronegative MCD [11,12].
3. Pathology
Two distinct variants have been described in CD: the hyaline vascular and plasma cell variant.
Where features of both these varieties occur, it is referred to as the mixed type or variant [2,5].
The hyaline vascular variant is characterised by follicles which show prominent vascular
proliferation and hyalinization of the central  portion.  There is  concentric layering of the
lymphocytes at the periphery of the follicles (mantle zone) – referred to as ‘target follicles’ and
imparting a classical ‘onion-skin’ appearance (see Figure 1). Another feature of this variety is
the presence of prominent sclerotic blood vessels which penetrate radially into the germinal
centres and transfix it, resulting in a ‘lollypop’ follicle appearance (see Figure 2). The interfollic‐
ular stroma is also prominent, with numerous hyperplastic vessels, plasma cells, eosinophils,
and immunoblasts. The hyaline vascular variety is most commonly associated with UCD [2,6].
The plasma cell variant is characterised by a diffuse interfollicular plasma cell proliferation.
Intermingled with the plasma cells are immunoblasts, lymphocytes, and histiocytes. Features
of the hyaline vascular variant are typically inconspicuous or absent. This variety is most
commonly associated with MCD [2,5,6]. The histopathological characteristic of MCD is the
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presence of large, abnormal plasmablasts located within the mantle zones of involved lymph
nodes [13,14].
The mixed variant or type of CD shares morphological features between the hyaline vascular
variant and plasma cell variant. It is classically encountered in MCD and is typically seen in
HIV-associated MCD [4,5].
Figure 1. Haematoxylin and Eosin stained section of lymph node (100× magnification) showing the concentric layering
of lymphocytes in the mantle zone of the lymphoid follicle – ‘onion-ring’ appearance
The pathogenesis of CD involves an interplay between viruses, namely HHV-8 and HIV,
cytokines such as IL-6 (interleukin-6) and IL-10, and growth factors such as VEGF (vascular
endothelial growth factor) [15,16].
Multicentric Castleman’s disease (MCD) is aetiologically linked to HHV-8 [7]. Human Herpes-
virus 8 is a gamma herpes virus and the causative organism in KS [17]. Soulier et al, 1995 [7],
showed that HHV-8 sequences were detected in lymph nodes in 14/14 (100%) cases of HIV-
associated MCD, compared to 7/17 (41%) cases with HIV-negative MCD. Other studies have
demonstrated an almost universal association of HHV-8 with HIV-associated MCD [11,18].
Interleukin-6 levels are increased in CD. A raised CRP, a surrogate marker for IL-6, anaemia,
hypergammaglobulinemia, plasmacytosis, splenomegaly, and lymphadenopathy are all
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associated with elevated levels of IL-6 [15,16]. Increased VEGF expression is also noted in CD
and is likely to be responsible for the increased angiogenesis component of the disease [19].
Figure 2. Haematoxylin and Eosin stained section of lymph node (200× magnification) showing the radially penetrat‐
ing blood vessels transfixing the germinal centre – ‘lollipop’ appearance
Figure 3. Human Herpesvirus-8 immunohistochemical stain showing mantle zone concentricity and distinct HHV-8
positive nuclear staining of lymphoid cells in the mantle zone (100× magnification)
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The diagnosis of CD is based on a combination of compatible clinical features together with
distinct histopathological features characteristic of the disease. Importantly, other benign and
malignant disorders with overlapping clinical and histological features should be excluded.
Recently, diagnostic criteria have been proposed for patients with MCD, particularly in
association with HIV [20,21]. These include the French ANRS (Agence Nationale de Recher‐
chesurle SIDA) criteria and the National Cancer Institute (NCI) criteria [20,21]. The diagnostic
criteria devised by these two groups complement the histopathological findings and are
particularly useful in those with idiopathic MCD. However, in HIV and HHV-8 associated
MCD, the histopathological diagnosis has been made much easier due to the presence of DNA
tests to detect HHV-8 in the blood and HHV-8 immunostaining of the tissue. Thus, Bower et
al, 2014 [22], suggest that in these individuals a triad of ‘B’ symptoms, elevated plasma HHV-8
levels and histopathological findings should suffice in making the diagnosis of MCD.
4. Clinical features and management
Two distinct clinical variants of Castleman’s disease are recognised: MCD and UCD. Unicen‐
tric Castleman’s disease (UCD) refers to localized disease, presenting at a single site, such as
the chest (most commonly the mediastinum), neck, abdomen, or other sites. Typically patients
are asymptomatic and come to clinical attention when an enlarged lymph node is noted on
physical examination or at imaging studies [1,2, 23]. 
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Figure 4. Bar graph which depicts the number of patients seen with Castleman’s disease at Chris Hani Baragwanath
Academic Hospital from 1990 to 2014
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Multicentric Castleman’s disease (MCD) refers to a systemic disease with constitutional
symptoms (fever, night sweats, weight loss), generalized lymphadenopathy and hepatosple‐
nomegaly. It is usually associated pathologically with the plasma cell or mixed variant. Unlike
UCD, MCD is strongly associated with HIV, immunosuppression and HHV-8 [11,23,24].
Laboratory studies usually reveal the presence of anaemia, a raised ESR, elevated CRP,
thrombocytopenia, hypoalbuminemia and polyclonal hypergammaglobulinemia [3, 4,11,15].
At Chris Hani Baragwanath Academic Hospital (CHBAH), Soweto, Johannesburg, a total of
38 patients were seen with CD over a 25-year period. Three of the patients (7.9%) were
diagnosed with UCD and 35 (92.1%) with MCD. Of all the patients with CD, 22/38 (57.9%)
were seen in the last 5 years compared to 42.1% in the first 20 years. The increase in the number
of patients with CD in the last 5 years is primarily as the result of the ongoing HIV pandemic
in South Africa and the contribution from HIV. Ninety five percent (21/22) of the patients seen
in the last five years and 100% of those with MCD were HIV seropositive.
Age Gender Site of lymph-adenopathy
Localised
or
systemic
disease
Anaemia (A) or
thrombocytopenia
(T)
Treatment HIV Response Outcome
1 18 M Mediastinum Localised No A or T Surgicalresection Negative
Complete
response Alive
2 64 F Inguino-femoral Localised No A or T
Surgical
resection Negative
Complete
response Alive
3 59 F Axilla Localised No A or T Surgicalresection Negative
Complete
response Alive
Table 1. Clinical characteristics of Unicentric Castleman’s disease
With regard to UCD, there were 2 females and 1 male, with a female to male ratio of 2:1. The
mean age at presentation was 47 years. All the patients were diagnosed post biopsy/resection
of localised nodal disease. None of the patients were HIV seropositive. No further treatment
was required in these patients after the initial surgical resection. All the patients are alive and
are well on observation (see Table 1).
A summary of the clinical characteristics of the patients with MCD is depicted in Table 2.
Characteristic Result/Finding
Number of patients 35
Median age; Mean age; Range Median = 36 years; Mean = 37years; Range = 18–64 years
Gender; ratio Males = 19, Females = 16; M:F ratio – 1.2:1
Multicentric disease 35/35 = 100%
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Characteristic Result/Finding
Fever 16/35 = 46%
‘B’ symptoms 23/35 = 66%
Lymphadenopathy 35/35 = 100%
Hepatomegaly 18/35 = 51%
Splenomegaly 20/35 = 57%
Anaemia (Hb<12 g/dl) 32/35 = 91%; Mean Hb = 7.8g/dl; Range = 2.8 – 13.5 g/dl
Thrombocytopenia (Platelets <100
× 109/l)
9/35 = 26%; Mean platelet count = 211 x 109/l; Range = 22 – 602 ×
109/l
HIV status (positive or negative) 30/35 = 86% positive; 5/35 = 14% negative
CD4 count × 106/l – mean and range; <350 × 106/l;
<200 x 106/l
Mean CD4 count = 257 × 106/l; Range = 12 – 829 × 106/l; <350 × 106/l
= 79%; <200 × 106/l = 46%
Morphology: i) Hyaline vascular (HV); ii) Plasma
cell (PC); Mixed (M)
HV only = 1/35 (3%); PC only = 1/35 (3%); Mixed = 34/35 (94%)
HHV-8 immunostain on biopsy Early part of the current series – not done. In the patients from
2010–2014, performed in 19/21 patients with MCD. The result was
positive in 19/19 patients = 100%
Associations Tuberculosis 15/35 = 43%; Kaposi’s sarcoma 8/35 = 23%;
Autoimmune haemolytic anaemia 6/35 = 17%; Pure red cell
aplasia 2/35 = 6% and 1/35 = 3% with each of the following –
primary effusion lymphoma, microlymphoma, adenocarcinoma,
bullous pemphigoid, immune thrombocytopenia, hepatitis B,
hepatitis C, hypoglycaemia and nephrotic syndrome
Response to treatment (evaluable patients – CR =
complete response; PR = partial response)
17/35 evaluable patients; CR 9/17 = 53%; PR = 47%
Outcome: Alive; Died (mean survival, range); Lost
to follow up (LTFU)
Alive 14/35 = 40%; Died = 34% (mean survival = 13 months, range
0.25 – 64 months); LTFU = 26%
Table 2. Summary of the clinical characteristics of Multicentric Castleman’s disease
5. Associations
Castleman’s disease may be seen in association with other diseases including POEMS syn‐
drome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein/gammopathy,
and skin changes/sclerotic bone lesions), paraneoplastic pemphigus, Kaposi's sarcoma,
Hodgkin lymphoma, Non Hodgkin lymphoma (in particular, primary effusion lymphoma
(PEL), and diffuse large B-cell lymphoma -DLBCL) [2,11, 22, 25,26,27].
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6. Management
Treatment modalities for CD include supportive care and specific modalities of treatment.
In the unicentric form of the disease, surgical resection of the localised site of the disease is
usually curative. However, follow up is recommended as patients may rarely relapse or
develop complications (such as an increased risk of lymphoma development) [23,26,28].
For MCD, a variety of specific treatment options are available, in addition to supportive care
(such as analgesia, allopurinol, transfusion of blood and blood products where indicated).
Specific treatment modalities include antiviral (anti-herpesvirus) and antiretroviral drugs
where a viral association is documented, corticosteroids, monoclonal antibodies, immunomo‐
dulatory agents (such as thalidomide), splenectomy, and radiotherapy [29].
Chemotherapy has evolved from single-agent (e.g. chlorambucil) to combination chemother‐
apy (cyclophosphamide, doxorubicin, vincristine, prednisone – CHOP), to the addition of
rituximab and etoposide [3,11,20,29,30,31]. Bower, 2010 [29], in his excellent review on ‘How
I treat HIV-associated multicentric Castleman disease’, uses a combination of weekly IVI
rituximab (375 mg/m2) with IVI etoposide (100 mg/m2) for 4 weeks for aggressive HIV-
associated MCD, with an overall 2 year survival of 85% and rituximab monotherapy (375 mg/
m2 weekly for 4 weeks) for low-risk HIV-associated MCD, with an overall 2 year survival of
100% [29].
For HIV-negative, HHV-8 negative MCD, other therapeutic options have been explored. This
includes monoclonal antibodies directed against IL-6 (siltuximab) or the IL-6 receptor (tocili‐
zumab) [27].
Multicentric Castleman’s disease (MCD) is increasingly being recognised as a relapsing and
remitting disease and in the HIV-seropositive setting is not necessarily suppressed or dimin‐
ished by combination antiretroviral therapy [29]. As such, the role of both rituximab and
antiherpesvirus agents such as valganciclovir have been explored as maintenance therapies
[20,29,32,33]. However, the role of maintenance therapy in this disease remains controversial
and requires further evaluation.
7. Discussion
Human immunodeficiency virus infection (HIV) is endemic in South Africa and is associated
with an increased risk of infection and malignancy, primarily as a consequence of immuno‐
deficiency [9]. The major impact of HIV on the haematological malignancies in South Africa
has been in regards to an increased prevalence of Non-Hodgkin lymphoma and, more recently,
Hodgkin lymphoma [34,35].
In South Africa, CD is rare. However, there has been a noticeable increase in MCD in the last
five years, with more than doubling of the number of patients in the last five years, compared
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to the previous twenty years (see Figure 4). This is attributable to the ongoing burden of HIV,
as the majority of patients in this series with MCD are HIV seropositive (86%).
There were 35 adult patients diagnosed with MCD over a 25-year period at CHBAH, a large,
tertiary, public sector, University of the Witwatersrand linked hospital, located in Soweto,
Johannesburg. The median age at presentation was 36 years (18–64 years), with a male to
female ratio of 1.2:1. The age is similar to that described in the literature. However, in our series,
there is no marked male predominance, as the major risk factor in our patients for acquisition
of HIV is heterosexual contact as compared to intravenous drug use or homosexuality.
The clinical presentation of MCD is similar to that described in the literature (see Table 2).
Fever, ‘B’ symptoms, lymphadenopathy, hepatosplenomegaly, and anaemia are commonly
encountered. Pathologically, the mixed variant is seen in 94% of the patients. The mean CD4
count in the HIV seropositive patients (86%) was 257 × 106/l, with 46% of the patients having
a CD4 count of < 200 × 106/l. Fifty three percent of the patients had newly diagnosed HIV (at
the time of the diagnosis of MCD) and 47% were known to be seropositive (86% of the positive
patients were on combination antiretroviral therapy). Concomitant Kaposi’s sarcoma was
diagnosed in 23% of patients. The HHV-8 immunostain performed on 19/21 patients with MCD
in the last five years was positive in 100% of the patients (see Figure 3). Other associations are
detailed in Table 2, most of these are related to coexistent HIV or HHV-8. Of note is the high
prevalence of concomitant tuberculosis (43%).
A variety of treatments were used over the past twenty years, ranging from symptomatic/
supportive treatment to corticosteroids, single agent chemotherapy, combination chemother‐
apy (such as CHOP and more recently the addition of etoposide to CHOP →  CHOEP),
rituximab together with CHOP or CHOEP, radiotherapy, and splenectomy. Of the evaluable
patients, 53% achieved a complete response to treatment and 47% manifested a partial response
to treatment. As our patients have more aggressive and advanced disease, the etoposide and
rituximab combinations are now being favoured. All the HIV seropositive patients receive
concomitant combination antiretroviral therapy.
Long term follow up is necessary to exclude relapse and complications of the disease, such as
the development of large cell lymphoma, which has a 15-fold increased incidence in patients
with HIV-associated MCD [36].
8. Conclusion
Multicentric Castleman’s disease is the most common form of CD encountered in our patients
at CHBAH. From being a rare disease, MCD has increased over the past few years, primarily
as a result of the association of HIV, being highly seroprevalent in our patient population. The
dominant clinical manifestation of MCD is lymphadenopathy. Therefore, the cause of signif‐
icant lymphadenopathy should always be defined, particularly in the setting of HIV. Most of
the patients were initially suspected of having a lymphoma, while others with HIV and
Kaposi’s sarcoma or autoimmune haemolytic anaemia had a lymph node biopsy to define the
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possible cause of the lymphadenopathy in association with the KS or AIHA. The prognosis of
HIV-associated MCD has improved with optimization and control of HIV replication (use of
combination antiretroviral therapy), prophylaxis, and treatment of opportunistic infections,
as well as etoposide and rituximab based chemotherapy. In the setting of HIV, MCD should
no longer be regarded as a rare disease with a fatal outcome.
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